Prostate Implants New Zealand Ltd logo Prostate Implants NZ Ltd provide effective treatment of prostate cancer Couple discuss brachytherapy treatment
Prostate cancer survivors enjoy their lives
Prostate Implants New Zealand specialists in brachytherapy for prostate cancer
Line of brachtherapy seeds
New Zealand specialists in brachytherapy for prostate cancer Survival rate for brachtherapy is 85% over 15 years
  Brachytherapy

Suitability

Pros & Cons

Treatment Costs

About Us

Quality Assurance

Scientific Papers

Helpful Resources

Contact Us

Disclaimer

Home

 

Scientific Publication

Initial 5 year Experience of Transperineal Permanent Iodine 125 Seed Implantation (TPSI) as Monotherapy for Prostate Cancer - Abstract in British Journal of Urology International, Vol 95, S1, p2

Scientific Papers Presented Include:

  1. Transperineal Permanent I-125 Seed prostate Implant - An Audit of Initial Experience, Annual Scientific Meeting, Royal Australian and New Zealand College of Radiologists, Auckland, October, 2000

  2. Transperineal Permanent I-125 Seed Implantation for Prostate Cancer- A quality outcomes Audit of the First 110 Patients, Annual Scientific meeting Royal Australasian College of Surgeons,, NZ Division, Palmerston North, September, 2001

  3. Transperineal Permanent I-125 Seed Implantation for Prostate Cancer- A quality outcomes Audit of the First 110 Patients Annual Scientific Meeting, Royal Australian and New Zealand College of Radiologists, Melbourne, Australia, October, 2001

  4. Practical Issues in Permanent Transperineal I-125 Seed Implantation of the Prostate. Invited Speaker at Australasian Brachytherapy Group Workshop, Gold Coast, 23 August 2002

  5. Technique for Transperineal Permanent Iodine 125 Seed Implantation for Prostate Cancer, - An overview of Implantation Technique, Invited Speaker, Australasian Brachytherapy Group Annual Scientific Meeting, Melbourne, Australia, April 2003

  6. Prospective Quality Assurance and Patient Toxicity of Transperineal Permanent Iodine 125 seed Implantation as Monotherapy for Prostate cancer - Results of initial 158 patients, Australasian Brachytherapy Group Annual Scientific Meeting, Melbourne, Australia, April 2003

  7. Initial 4 year Experience of Serum PSA Kinetics after TPSI as Monotherapy for Prostate Cancer, Australasian Brachytherapy Group Annual Scientific Meeting, Hobart, Australia, March 2004

  8. Late Effects of TPSI as Monotherapy for Prostate Cancer, NZ Uro Oncology Group Annual scientific Meeting, Hamner Springs, August 2004

  9. The Initial 5 year Experience of Transperineal Permanent Iodine 125 Seed Implantation for Prostate Cancer, Annual scientific Meeting Royal Australian and New Zealand College of Radiologists, Perth, October 2004